Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | TACR3 | P29371 | 10/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383432 | 1.00 | CYP2C9 (0.42) | CYP2C9TACR3TRPV1ROCK2 | |
| SCHEMBL2370656 | 0.82 | CYP2C9 (0.47) | CYP2C9TACR3TRPV1ROCK2 | |
| SCHEMBL2154827 | 0.81 | TACR3 (0.41) | CYP2C9TACR3 | |
| SCHEMBL2370709 | 0.79 | CYP2C9 (0.45) | CYP2C9TACR3TRPV1ROCK2 | |
| SCHEMBL2171938 | 0.79 | CYP2C9 (0.40) | CYP2C9TACR3 | |
| SCHEMBL2171945 | 0.79 | CYP2C9 (0.40) | CYP2C9TACR3 | |
| SCHEMBL2371286 | 0.78 | CYP2C9 (0.44) | CYP2C9TACR3TRPV1ROCK2 | |
| SCHEMBL12301416 | 0.74 | CYP2C9 (0.47) | CYP2C9TACR3TRPV1ROCK2 | |
| SCHEMBL2156140 | 0.73 | TACR3 (0.40) | CYP2C9TACR3 | |
| SCHEMBL2156148 | 0.73 | TACR3 (0.40) | CYP2C9TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2013-07-25 | — | — | US | disclosed |
| EP-2545053-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2013-01-16 | — | — | EP | disclosed |
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110183-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224247-A1 | AZAISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, KCND3 | CYP2C9 4124/4885TACR3 12/4885TRPV1 1538/4885 |
| US-20130190499-A1 | Azaisoquinolinone derivatives as NK3 antagonists | KCNQ3, KCNK3, KCND3 | CYP2C9 4124/4885TACR3 12/4885TRPV1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.